Health & Fitness
Wed, November 23, 2011
ELMWOOD PARK, N.J.--([ BUSINESS WIRE ])--[ Bio-Reference Laboratories, Inc ]. (NASDAQ: BRLI) announced today that it has entered into a purchasing agreement with a McKesson Specialty Health group purchasing organization (GPO), the Onmark GPO. The Onmark GPO delivers a range of services to its members that now include a contract for the routine and specialized services of the Bio-Reference family of clinical diagnostic services. Onmark GPO is one of the solutions delivered to community-based practices through the Onmark Select Program. Onmark Select delivers a broad set of proven, customizable solutions that includes GPO services as well as differentiated technology, revenue cycle and payer solutions, clinical tools, business resources and clinical trial support.
Marc Grodman, CEO of BRLI, noted: aMcKesson Specialty Healthas Onmark Select Program is a premier solution for community-based practices throughout the country, and we are proud to have been selected as a participating laboratory by its Onmark GPO. We believe that this will afford Onmark GPO members a unique opportunity to take advantage of the cutting-edge solutions being offered by BRLI. We offer a full spectrum of diagnostic solutions that enable clinical providers to offer improved healthcare to their patients, and we look forward to a productive arrangement with the provider members of the Onmark Select Program.a
About BioReference Laboratories, Inc.
BRLI is the fourth largest full service laboratory in the United States and the largest independent regional laboratory in the Northeastern market, primarily a clinical testing laboratory servicing physician offices with concentrations in the focused markets of esoteric testing, molecular diagnostics, anatomical pathology, womenas health and correctional health care. BRLI operates as a national oncology laboratory as GenPath. Better science, superior technology and better service have enabled GenPath to earn a reputation as one of the premier hematopathology laboratories in the country. BRLIas innovative technology platform for sexually transmitted infections has enabled it to expand as a national laboratory in the area of Womenas Health. GeneDx, a wholly owned subsidiary, is the BRLI genetics laboratory and is typically recognized as the leading laboratory for testing of rare genetic diseases; GeneDx has now become a technology leader with GenomeDx, based on a CGH array platform and its NextGen sequence offerings that are currently offered in cardiology and will be offered in the future in other disease specific areas.
Statements included in this release that are not historical in nature, are intended to be, and are hereby identified as aforward-looking statementsa. Statements looking forward in time are included in this release pursuant to the asafe harbora provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks and uncertainties that may cause the Companyas actual results in future periods to be materially different from any future performance suggested herein.
